Can Burn Injury Cause Thrombotic Thrombocytopenic Purpura?

Mehmet Akif Öztürk, Nisa Babacanlar, Cafer Akkoz, Ali Özdemir

Thrombotic thrombocytopenic purpura (TTP) is characterized by the pentad of microangiopathic hemolytic anemia, uremia, thrombocytopenia, neurological symptoms, and fever. It can be a fatal emergency if early diagnosis and appropriate evaluation are not performed. TTP is associated with an acquired or congenital deficiency of the von Willebrand factor-cleaving metalloprotease, ADAMTS13. It can be triggered by many diseases or drugs. Plasma exchange, which is an urgent treatment modality, can be effective in cases of TTP. Presently described is the case of a 35-year-old man with a diagnosis of TTP that developed after a burn injury. The underlying mechanism of TTP development after a burn is still unknown. Clinicians should pay attention to neurological symptoms and thrombocytopenia after burn accidents and must be alert to this life-threatening situation.

INTRODUCTION

Thrombotic thrombocytopenic purpura (TTP) is characterised by the pentad of microangiopathic hemolytic anemia, uremia, thrombocytopenia, neurological symptoms and fever. It may prove to be fatal if early diagnosis and appropriate evaluation is not done. Here we report the case of a patient in whom TTP developed after a burn injury.

CASE REPORT

A 35-year-old man was admitted to emergency department with the complaints of headache, fever, dysarthria and dysaesthesia. Tonic convulsions and agitation were observed following plegia of upper extremities in the emergency department. His past medical history comprised a second-degree burn on his left upper extremity and face (13% of the total body) 15 days ago. There was no history of drug use. Physical examination showed a body temperature of 38°C, heart rate of 88 bpm, blood pressure of 140/90 mmHg, oxygen saturation of 99% and Glasgow Coma Scale (GCS) score of 8. His complete blood count showed that he had thrombocytopenia (platelet count 19,000 μ/L), anaemia (haemoglobin concentration 7.7 g/dL, haematocrit 23.2%) and leucocytosis (white blood cell count 15,700 μ/L). Furthermore, his biochemical tests showed increased lactate dehydrogenase (LDH, 1323 U/L), blood urea nitrogen (BUN, 20 mg/dL), creatinine (1.49 mg/dL) and total bilirubin (2.31 mg/dL) levels. Coagulation tests, D-dimer and fibrinogen levels were normal. Fragmented erythrocytes were observed in his blood smear (Fig. 1). Blood sample was collected for ADAMTS13 measurement. On the basis of the above clinical and laboratory findings, the patient was diagnosed with TTP and was transferred to intensive care unit. Treatment with a corticosteroid (1 mg/kg) and plasmapheresis were simultaneously started. The clinical condition of the patient improved, and his GCS score increased to 15 after 3 cycles of plasmapheresis. Furthermore, his laboratory test values improved with a platelet count of 351,000 μ/L; haemoglobin concentration of 10.3 g/dL; and BUN, creatinine and LDH levels of 23 mg/dL, 0.9 mg/dL and 329 U/L, respectively. ADAMTS13 activity was detected to be <10% in the blood sample collected before plasmapheresis.
DISCUSSION

TTP was first described by Moschcowitz in 1924. TTP is associated with acquired or congenital deficiency of the von Willebrand factor-cleaving metalloprotease, ADAMTS13. It is characterised by the pentad of microangiopathic haemolytic anaemia, fever, neurological symptoms, thrombocytopenia and acute renal failure. The incidence of acquired TTP is 3 cases per million population.[1]

Pathophysiologically, undetectable levels of enzyme activity or an autoantibody to ADAMTS13 leads to the activation of coagulation cascade that subsequently results in platelet aggregation, microembolus of the small vessels and erythrocyte fragmentation. These pathophysiological features of the disease cause microangiopathic haemolytic anaemia and thrombocytopenia. The presence of ADAMS-13 inhibitor is important for the acquired or hereditary discrimination. Diseases such as disseminated intravascular coagulation, Evans syndrome and systemic lupus erythematosus may be considered in the differential diagnosis of microangiopathic haemolytic anaemia and thrombocytopenia. Our patient exhibited all the elements of the TTP pentad.

Plasma exchange, which is an urgent treatment modality, is effective in TTP.[4–6] Simultaneous glucocorticoid administration in addition to plasma exchange is a preferred treatment method.[7,8] We used both plasma exchange and glucocorticoids in our patient and achieved a satisfactory result with the treatment.

TTP can be triggered by many diseases or drugs. We believe that it was triggered by burns in the present case. The appearance of the condition 15 days after the burn event is thought to be associated with a slow immune mechanism. To the best of our knowledge, burn-induced TTP has not yet been reported. Thus, this case is different from other reported cases of TTP. Previously, the case of a 1-year-old child who developed haemolytic uremic syndrome after a burn injury has been reported.[9] The underlying mechanism of TTP development after burn is unknown.

In conclusion, clinicians should pay attention to neurological symptoms and thrombocytopenia after burn accidents and must be aware about this life-threatening situation.

REFERENCES

Yanık Hasarı Trombotik Trombositopenik Purpuraya Yol Açar mı?


Anahtar Sözcükler: Anemi; trombotik trombositopenik purpura; yanık.